High Fructose Corn Syrup Accelerates Kidney Disease and Mortality in Obese Mice with Metabolic Syndrome
Biomolecules · 30.04.2023 · 13 (5) · 780
DOI: 10.3390/biom13050780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 30.04.2023. Verfasst von Ana Andres-Hernando und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Metabolic Syndrome, High Fructose Corn Syrup, Kidney Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIDDK NIH HHS, NIH R01.
Abstract (Originalsprache)
The presence of obesity and metabolic syndrome is strongly linked with chronic kidney disease (CKD), but the mechanisms responsible for the association are poorly understood. Here, we tested the hypothesis that mice with obesity and metabolic syndrome might have increased susceptibility to CKD from liquid high fructose corn syrup (HFCS) by favoring the absorption and utilization of fructose. We evaluated the pound mouse model of metabolic syndrome to determine if it showed baseline differences in fructose transport and metabolism and whether it was more susceptible to chronic kidney disease when administered HFCS. Pound mice have increased expression of fructose transporter (Glut5) and fructokinase (the limiting enzyme driving fructose metabolism) associated with enhanced fructose absorption. Pound mice receiving HFCS rapidly develop CKD with increased mortality rates associated with intrarenal mitochondria loss and oxidative stress. In pound mice lacking fructokinase, the effect of HFCS to cause CKD and early mortality was aborted, associated with reductions in oxidative stress and fewer mitochondria loss. Obesity and metabolic syndrome show increased susceptibility to fructose-containing sugars and increased risk for CKD and mortality. Lowering added sugar intake may be beneficial in reducing the risk for CKD in subjects with metabolic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Metabolism and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Division of Nephrology, Rocky Mountain VA Medical Center, Aurora, CO 80045, USA.
- Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Division of Cardiovascular Disease, Toranomon Hospital, Tokyo 105-8470, Japan.
- Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Regenerative Medicine Development, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu 520-2192, Japan.
ORCID-Profile: David J Orlicky, Masanari Kuwabara, Laura Gabriela Sanchez-Lozada, Richard J Johnson
Förderung
- BLRD VA
- NIDDK NIH HHS
- NIH R01
- VA Merit
Zitieren
APA
Andres-Hernando, A., Orlicky, D. J., Cicerchi, C., Kuwabara, M., Garcia, G. E., Nakagawa, T., Sanchez-Lozada, L. G., Johnson, R. J., & Lanaspa, M. A. (2023). High Fructose Corn Syrup Accelerates Kidney Disease and Mortality in Obese Mice with Metabolic Syndrome. Biomolecules, 13(5), 780. https://doi.org/10.3390/biom13050780
Vancouver
Andres-Hernando A, Orlicky DJ, Cicerchi C, Kuwabara M, Garcia GE, Nakagawa T, et al. High Fructose Corn Syrup Accelerates Kidney Disease and Mortality in Obese Mice with Metabolic Syndrome. Biomolecules. 2023;13(5):780. doi:10.3390/biom13050780
BibTeX
@article{AndresHernando2023,
author = {Andres-Hernando, Ana and Orlicky, David J and Cicerchi, Christina and Kuwabara, Masanari and Garcia, Gabriela E and Nakagawa, Takahiko and Sanchez-Lozada, Laura Gabriela and Johnson, Richard J and Lanaspa, Miguel A},
title = {High Fructose Corn Syrup Accelerates Kidney Disease and Mortality in Obese Mice with Metabolic Syndrome},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {5},
pages = {780},
doi = {10.3390/biom13050780}
}
EUVIMED